AbbVie Inc.Long
ABBV, is it a buy right now?
☝️ Losing patent protection for a top-selling blockbuster drug is a big setback for any pharmaceutical company, but this can also give us great opportunities. They have done a great strategic-movement by acquiring Allergan.
It's down 18% from last July 17 high, earnings are close. I believe, yes, it's a good moment to START doing COST-AVERAGE.
The price is almost getting closer to the 50% Fibonacci (from last Mar 20). I'm protecting an optimistic retracement to 127% (at $108.58) Fibonacci (drawing from today), very close to the analyst's current average price target at $109.21. A more conservative take profit would be at $95.
- P/E GAAP (TTM) of 18.63, sector media of 35.57 👍
- Forward P/E of 6.94 👍
- PEG GAAP (TTM) of 0.29, sector media of 0.88 👍
- EV / EBITDA (TTM) of 13.76 in a sector media of 19.29 👍
- Debt / Eq of 5.4 😐
- Dividend yield of 5.60% 😍
Nothing else to say, it's a great company, with great dividends. I'm in! 👌
This isn't trading advice. I've no idea what I'm talking about 😉.
Trade with caution! 🚨
Have a good day! 🤟
It's down 18% from last July 17 high, earnings are close. I believe, yes, it's a good moment to START doing COST-AVERAGE.
The price is almost getting closer to the 50% Fibonacci (from last Mar 20). I'm protecting an optimistic retracement to 127% (at $108.58) Fibonacci (drawing from today), very close to the analyst's current average price target at $109.21. A more conservative take profit would be at $95.
- P/E GAAP (TTM) of 18.63, sector media of 35.57 👍
- Forward P/E of 6.94 👍
- PEG GAAP (TTM) of 0.29, sector media of 0.88 👍
- EV / EBITDA (TTM) of 13.76 in a sector media of 19.29 👍
- Debt / Eq of 5.4 😐
- Dividend yield of 5.60% 😍
Nothing else to say, it's a great company, with great dividends. I'm in! 👌
This isn't trading advice. I've no idea what I'm talking about 😉.
Trade with caution! 🚨
Have a good day! 🤟
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.